FOLH1 and neoplasm: Nuclear imaging for bone metastasis detection relies on different radiotracers that offer insights into tumor activity, either directly (e.g.,18F-fluorodeoxyglucose (18F-FDG), 18F-Fluorocholine (18F-FCH), 18F-or 68Ga-radiolabeled prostate-specific membrane antigen (PSMA), 18F-Fluoro-dihydroxyphenylalanine (18F-DOPA), radiolabeled somatostatin analogs like 68Ga-DOTA-peptides) or indirectly, often through the assessment of osteoblastic markers [bisphosphonates labeled with 99mTc, and 18F-Fluoride (18F-NaF)].